Published

Multilevel Mechanisms and Clinical Efficacy of Psilocybin in Depression Treatment: A Systematic Review

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: International Journal of Molecular Sciences
Date: 2026-09-10
Source: Crossref
DOI: 10.3390/ijms27188052
PubMed: Unavailable

Authors

Zhang Xizhen Zhang Xiaowen Zhang Haiyu Wei Sheng

Watch author

Derived topics and classifications

psilocybin psilocin Depression Neurogenesis Mechanism of Action Receptor Pharmacology Default Mode Network Clinical Trial Systematic Review Review Article Treatment-Resistant Depression Systematic Review

Citation graph

40 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

10.1017/s0033291725000303 10.1186/s12888-025-06828-x 10.1016/s2215-0366(19)30032-x 10.1007/s12035-022-02780-z 10.1007/s13311-022-01270-3 10.1016/j.scib.2024.11.033 10.1016/j.neuropharm.2018.02.018 10.1038/s41591-025-04194-5 10.1038/s41593-023-01316-5 10.1038/s41514-025-00244-x 10.1007/s44192-026-00384-w 10.1080/13543784.2023.2273493

Indexed papers citing this DOI

Multilevel Mechanisms and Clinical Efficacy of Psilocybin in Depression Treatment: A Systematic Review2026-09-10

Related papers

Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial.Trials · 2024-05-21 A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10 A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10 Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness (PDR-Study)ClinicalTrials.gov · 2025-05-28 A One-Year Observational Follow-up Study of Participants With Major Depressive Disorder Following a Randomized, Double-Blind Single-Dose of Psilocybin or Niacin-ControlClinicalTrials.gov · 2026-05-04 S1 Appendix - Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trialFigshare · 2025-09-19 A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive DisorderClinicalTrials.gov · 2025-08-19 Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression.Trials · 2024-07-03